Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
<p>Evaluation of circulating CD4+ T cell subsets. (A) Changes in regulatory T cells (Tregs) during treatment compared to screening in the entire patient cohort. (B) Changes in levels of circulating CD4+ naïve (CD45RA+ CCR7+), central memory (CM; CD45RA- CCR7+), effector memory (EM; CD45RA- CCR...
Zapisane w:
| 1. autor: | |
|---|---|
| Kolejni autorzy: | , , , , , , , , , , , , , , , , , , , , |
| Wydane: |
2025
|
| Hasła przedmiotowe: | |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|
| _version_ | 1849927633334173696 |
|---|---|
| author | Dwight H. Owen (15034782) |
| author2 | Brooke Benner (15054338) Lai Wei (15023852) Vineeth Sukrithan (15054341) Ashima Goyal (15054344) Ye Zhou (15054347) Carly Pilcher (15054350) Sheryl-Ann Suffren (15054353) Gwen Christenson (15054356) Nancy Curtis (15054359) Megan Jukich (15054362) Emily Schwarz (15054365) Himanshu Savardekar (15054368) Ruthann Norman (15054371) Sarah Ferguson (15054374) Barbara Kleiber (15054377) Robert Wesolowski (8863505) William E. Carson (15054380) Gregory A. Otterson (15054383) Claire F. Verschraegen (15054386) Manisha H. Shah (15054389) Bhavana Konda (15054392) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Dwight H. Owen (15034782) Brooke Benner (15054338) Lai Wei (15023852) Vineeth Sukrithan (15054341) Ashima Goyal (15054344) Ye Zhou (15054347) Carly Pilcher (15054350) Sheryl-Ann Suffren (15054353) Gwen Christenson (15054356) Nancy Curtis (15054359) Megan Jukich (15054362) Emily Schwarz (15054365) Himanshu Savardekar (15054368) Ruthann Norman (15054371) Sarah Ferguson (15054374) Barbara Kleiber (15054377) Robert Wesolowski (8863505) William E. Carson (15054380) Gregory A. Otterson (15054383) Claire F. Verschraegen (15054386) Manisha H. Shah (15054389) Bhavana Konda (15054392) |
| author_role | author |
| dc.creator.none.fl_str_mv | Dwight H. Owen (15034782) Brooke Benner (15054338) Lai Wei (15023852) Vineeth Sukrithan (15054341) Ashima Goyal (15054344) Ye Zhou (15054347) Carly Pilcher (15054350) Sheryl-Ann Suffren (15054353) Gwen Christenson (15054356) Nancy Curtis (15054359) Megan Jukich (15054362) Emily Schwarz (15054365) Himanshu Savardekar (15054368) Ruthann Norman (15054371) Sarah Ferguson (15054374) Barbara Kleiber (15054377) Robert Wesolowski (8863505) William E. Carson (15054380) Gregory A. Otterson (15054383) Claire F. Verschraegen (15054386) Manisha H. Shah (15054389) Bhavana Konda (15054392) |
| dc.date.none.fl_str_mv | 2025-11-25T13:05:29Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30707303 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_2_from_A_Phase_II_Clinical_Trial_of_Nivolumab_and_Temozolomide_for_Neuroendocrine_Neoplasms/30707303 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Chemotherapy Combination chemotherapy Clinical Trial Results Phase II clinical trials Endocrine-Related Cancers Immunotherapy Checkpoint blockade Lung Cancer |
| dc.title.none.fl_str_mv | Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Evaluation of circulating CD4+ T cell subsets. (A) Changes in regulatory T cells (Tregs) during treatment compared to screening in the entire patient cohort. (B) Changes in levels of circulating CD4+ naïve (CD45RA+ CCR7+), central memory (CM; CD45RA- CCR7+), effector memory (EM; CD45RA- CCR7-), and terminal effector memory (TE; CD45RA+ CCR7-) subsets at screening and cycle 1, day 15 (C1D15) of nivolumab and temozolomide treatment in the entire study cohort. (C) Levels of co-inhibitory molecules PD-1, LAG3, TIM3, and KLRG1 on circulating CD4+ T cells on study treatment compared to screening. Each symbol represents one patient (n = 9). Line indicates mean, *p<0.05.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_be6a58f8b765eb36787b2f3c71f0558f |
| identifier_str_mv | 10.1158/1078-0432.30707303 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30707303 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine NeoplasmsDwight H. Owen (15034782)Brooke Benner (15054338)Lai Wei (15023852)Vineeth Sukrithan (15054341)Ashima Goyal (15054344)Ye Zhou (15054347)Carly Pilcher (15054350)Sheryl-Ann Suffren (15054353)Gwen Christenson (15054356)Nancy Curtis (15054359)Megan Jukich (15054362)Emily Schwarz (15054365)Himanshu Savardekar (15054368)Ruthann Norman (15054371)Sarah Ferguson (15054374)Barbara Kleiber (15054377)Robert Wesolowski (8863505)William E. Carson (15054380)Gregory A. Otterson (15054383)Claire F. Verschraegen (15054386)Manisha H. Shah (15054389)Bhavana Konda (15054392)CancerTherapeutic Research and DevelopmentImmuno-oncologyClinical Research and TrialsChemotherapyCombination chemotherapyClinical Trial ResultsPhase II clinical trialsEndocrine-Related CancersImmunotherapyCheckpoint blockadeLung Cancer<p>Evaluation of circulating CD4+ T cell subsets. (A) Changes in regulatory T cells (Tregs) during treatment compared to screening in the entire patient cohort. (B) Changes in levels of circulating CD4+ naïve (CD45RA+ CCR7+), central memory (CM; CD45RA- CCR7+), effector memory (EM; CD45RA- CCR7-), and terminal effector memory (TE; CD45RA+ CCR7-) subsets at screening and cycle 1, day 15 (C1D15) of nivolumab and temozolomide treatment in the entire study cohort. (C) Levels of co-inhibitory molecules PD-1, LAG3, TIM3, and KLRG1 on circulating CD4+ T cells on study treatment compared to screening. Each symbol represents one patient (n = 9). Line indicates mean, *p<0.05.</p>2025-11-25T13:05:29ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30707303https://figshare.com/articles/figure/Supplementary_Figure_2_from_A_Phase_II_Clinical_Trial_of_Nivolumab_and_Temozolomide_for_Neuroendocrine_Neoplasms/30707303CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307073032025-11-25T13:05:29Z |
| spellingShingle | Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms Dwight H. Owen (15034782) Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Chemotherapy Combination chemotherapy Clinical Trial Results Phase II clinical trials Endocrine-Related Cancers Immunotherapy Checkpoint blockade Lung Cancer |
| status_str | publishedVersion |
| title | Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_full | Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_fullStr | Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_full_unstemmed | Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_short | Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_sort | Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| topic | Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Chemotherapy Combination chemotherapy Clinical Trial Results Phase II clinical trials Endocrine-Related Cancers Immunotherapy Checkpoint blockade Lung Cancer |